Serena Dienes

Serena Dienes

Auto-generated profile, based on publicly available information

Serena Dienes

Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2024 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
RARaed Alhusayen
Raed Alhusayen
SDSerena Dienes
Serena Dienes
MLMegan Lam
Megan Lam
AAAfsaneh Alavi
Afsaneh Alavi
AAAli Alikhan
Ali Alikhan
HNHaley B. Naik
Haley B. Naik
Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease. Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation system to ascertain level of evidence and selected through a modified Delphi consensus process. One hundred eighteen expert consensus statements are provided for the management of patients with HS across these 7 special patient populations.

26 July 2024 in Journal of Orthopaedics
Verified
Journal Article
Open access
AEAli Etemad-Rezaie
Ali Etemad-Rezaie
SDSerena Dienes
Serena Dienes
CGChetan Gohal
Chetan Gohal
VPValerie Politis-Barber
Valerie Politis-Barber
SSStephanie Searle
Stephanie Searle
USUjash Sheth
Ujash Sheth
To systematically identify and evaluate different bone graft augmentation techniques in the operative treatment of complex proximal humerus fractures. Four databases were searched from 1970 to February 2023 for Level I to IV English studies that investigated outcomes of different bone augments in the primary surgical fixation of proximal humerus fractures. The JBI critical appraisal checklist, methodological index for non-randomized studies and cochrane risk of bias tool were used to assess study quality. Descriptive statistics including weighted means are presented where applicable. Thirty-three articles including 964 patients met the inclusion. Seven bone augments were identified, including fibular strut allograft (693 patients across 21 studies), femoral head allograft (84 patients across 4 studies), iliac crest allograft (54 patients across 3 studies), iliac crest autograft (94 patients across 5 studies), humeral endosteal allograft (6 patients in 1 single study), unspecified cancellous allograft (28 patients in 1 single study) and distal clavicle autograft (3 patients in 1 single study). Mean patient age was 67.1 years, with female patients comprising 65.2 %. Fracture union rates were similar between groups, with an average of 99.6 %. The average Constant Murley Score (CMS) was not reported in the humeral endosteal allograft or the distal clavicle autograft group but was 81.8 (fibular strut allograft), 79.1 (femoral head allograft), 76.8 (iliac crest allograft), 77.7 (iliac crest autograft), and 81.5 (unspecified cancellous allograft) in the remaining groups. Revision surgery was required in 16.7 % of patients receiving humeral endosteal allograft, 7 % of patients with femoral head allograft, 2 % of iliac crest autografts and 1.9 % in the fibular allograft group. Reported complications included avascular necrosis, hardware complications and loss of reduction. Bone graft augmentation is an effective adjunct to open reduction internal fixation of complex proximal humerus fractures. Fibular strut allograft is the most common bone graft augment used. Majority of patients treated with bone graft augmentation achieved bony union (83%-100 %) and average CMS scores at final follow-up were similar between graft types (76-82). However, no conclusive data suggests superiority of one bone graft type over another. Future studies should aim to compare the outcomes amongst graft types.

12 February 2026 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Open access
SDSerena Dienes
Serena Dienes
ARArya Rahmani
Arya Rahmani
ILIrene Lara-Corrales
Irene Lara-Corrales
RLRebecca Levy
Rebecca Levy
RARaed Alhusayen
Raed Alhusayen
CSCathryn Sibbald
Cathryn Sibbald
Background: Hidradenitis suppurativa (HS) is a highly comorbid condition understudied in pediatric populations. Furthermore, the underrepresentation of Canadians in HS research limits our evaluation of care in real-world Canadian settings. Objectives: To describe the demographics, clinical characteristics, psychosocial burden, and management of pediatric HS at a Canadian hospital. Methods: We developed the infrastructure for a Canada-wide HS registry and piloted it at a pediatric HS tertiary care centre. A retrospective review of patients seen was performed using data collection forms (DCFs) developed for the registry. Results: The 39 patients included were 53.8% female and 100.0% nonsmokers. Asians were overrepresented compared to other North American studies. Most had Hurley stage II (60.5%) or III (28.9%) disease. Mean delay to diagnosis was 2.1 ± 2.0 years. Obesity (57.9%), acne (30.7%), folliculitis (23.1%), and trisomy 21 (23.1%) were the most common comorbidities. Patients with trisomy 21 had an age of HS onset 3 years younger ( P = .0087), and 44.0% had concomitant disseminate and recurrent infundibulofolliculitis. Moderate-to-severe quality of life (QOL) impact was seen in 56.8% of patients, and 17.6% had reported bullying. Of patients prescribed biologics (59.0%), most used 1 (56.6%), while 39.1% switched to a second and 4.3% to a third biologic. Most adalimumab-initiated patients clinically improved (81.0%), but only 2 patients achieved complete remission. Follow-up patients (n = 14) had significant improvements in QOL ( P = .038) and pain ( P = .026) scores. Conclusions: Distinct demographics, severe disease, and low remission rates characterized our complex HS cohort. Prospective use of these DCFs will enhance our understanding of HS in Canada.

25 February 2025 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
SDSerena Dienes
Serena Dienes
IUInna Ushcatz
Inna Ushcatz
ARArya Rahmani
Arya Rahmani
KSKyle Seigel
Kyle Seigel
DCDavid Croitoru
David Croitoru
VPVincent Piguet
Vincent Piguet

18 April 2025 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
DSDarshana Seeburruth
Darshana Seeburruth
SDSerena Dienes
Serena Dienes
YPYe-Jean Park
Ye-Jean Park
MSMuskaan Sachdeva
Muskaan Sachdeva
SJShubhreet Johal
Shubhreet Johal
SHSameh Hanna
Sameh Hanna

20 April 2025 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
DSDarshana Seeburruth
Darshana Seeburruth
SDSerena Dienes
Serena Dienes
MSMuskaan Sachdeva
Muskaan Sachdeva
MMMehnaz Munir
Mehnaz Munir
EAEunice Aluko
Eunice Aluko
MJMarissa Joseph
Marissa Joseph